Cargando…
Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities
Sarcomas are rare and heterogeneous mesenchymal neoplasms originating from the bone or soft tissues, which pose significant treatment challenges. The current standard treatment for sarcomas consists of surgical resection, often combined with chemo- and radiotherapy; however, local recurrence and met...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for Molecular and Cellular Biology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590708/ https://www.ncbi.nlm.nih.gov/pubmed/37853684 http://dx.doi.org/10.14348/molcells.2023.0079 |
_version_ | 1785124048063168512 |
---|---|
author | Jeong, Sehan Afroz, Sharmin Kang, Donghyun Noh, Jeonghwan Suh, Jooyeon Kim, June Hyuk You, Hye Jin Kang, Hyun Guy Kim, Yi-Jun Kim, Jin-Hong |
author_facet | Jeong, Sehan Afroz, Sharmin Kang, Donghyun Noh, Jeonghwan Suh, Jooyeon Kim, June Hyuk You, Hye Jin Kang, Hyun Guy Kim, Yi-Jun Kim, Jin-Hong |
author_sort | Jeong, Sehan |
collection | PubMed |
description | Sarcomas are rare and heterogeneous mesenchymal neoplasms originating from the bone or soft tissues, which pose significant treatment challenges. The current standard treatment for sarcomas consists of surgical resection, often combined with chemo- and radiotherapy; however, local recurrence and metastasis remain significant concerns. Although immunotherapy has demonstrated promise in improving long-term survival rates for certain cancers, sarcomas are generally considered to be relatively less immunogenic than other tumors, presenting substantial challenges for effective immunotherapy. In this review, we examine the possible opportunities for sarcoma immunotherapy, noting cancer testis antigens expressed in sarcomas. We then cover the current status of immunotherapies in sarcomas, including progress in cancer vaccines, immune checkpoint inhibitors, and adoptive cellular therapy and their potential in combating these tumors. Furthermore, we discuss the limitations of immunotherapies in sarcomas, including a low tumor mutation burden and immunosuppressive tumor microenvironment, and explore potential strategies to tackle the immunosuppressive barriers in therapeutic interventions, shedding light on the development of effective and personalized treatments for sarcomas. Overall, this review provides a comprehensive overview of the current status and potential of immunotherapies in sarcoma treatment, highlighting the challenges and opportunities for developing effective therapies to improve the outcomes of patients with these rare malignancies. |
format | Online Article Text |
id | pubmed-10590708 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Korean Society for Molecular and Cellular Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-105907082023-10-24 Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities Jeong, Sehan Afroz, Sharmin Kang, Donghyun Noh, Jeonghwan Suh, Jooyeon Kim, June Hyuk You, Hye Jin Kang, Hyun Guy Kim, Yi-Jun Kim, Jin-Hong Mol Cells Minireview Sarcomas are rare and heterogeneous mesenchymal neoplasms originating from the bone or soft tissues, which pose significant treatment challenges. The current standard treatment for sarcomas consists of surgical resection, often combined with chemo- and radiotherapy; however, local recurrence and metastasis remain significant concerns. Although immunotherapy has demonstrated promise in improving long-term survival rates for certain cancers, sarcomas are generally considered to be relatively less immunogenic than other tumors, presenting substantial challenges for effective immunotherapy. In this review, we examine the possible opportunities for sarcoma immunotherapy, noting cancer testis antigens expressed in sarcomas. We then cover the current status of immunotherapies in sarcomas, including progress in cancer vaccines, immune checkpoint inhibitors, and adoptive cellular therapy and their potential in combating these tumors. Furthermore, we discuss the limitations of immunotherapies in sarcomas, including a low tumor mutation burden and immunosuppressive tumor microenvironment, and explore potential strategies to tackle the immunosuppressive barriers in therapeutic interventions, shedding light on the development of effective and personalized treatments for sarcomas. Overall, this review provides a comprehensive overview of the current status and potential of immunotherapies in sarcoma treatment, highlighting the challenges and opportunities for developing effective therapies to improve the outcomes of patients with these rare malignancies. Korean Society for Molecular and Cellular Biology 2023-10-31 2023-09-22 /pmc/articles/PMC10590708/ /pubmed/37853684 http://dx.doi.org/10.14348/molcells.2023.0079 Text en © The Korean Society for Molecular and Cellular Biology. All rights reserved. https://creativecommons.org/licenses/by-nc-sa/3.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ (https://creativecommons.org/licenses/by-nc-sa/3.0/) |
spellingShingle | Minireview Jeong, Sehan Afroz, Sharmin Kang, Donghyun Noh, Jeonghwan Suh, Jooyeon Kim, June Hyuk You, Hye Jin Kang, Hyun Guy Kim, Yi-Jun Kim, Jin-Hong Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities |
title | Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities |
title_full | Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities |
title_fullStr | Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities |
title_full_unstemmed | Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities |
title_short | Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities |
title_sort | sarcoma immunotherapy: confronting present hurdles and unveiling upcoming opportunities |
topic | Minireview |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590708/ https://www.ncbi.nlm.nih.gov/pubmed/37853684 http://dx.doi.org/10.14348/molcells.2023.0079 |
work_keys_str_mv | AT jeongsehan sarcomaimmunotherapyconfrontingpresenthurdlesandunveilingupcomingopportunities AT afrozsharmin sarcomaimmunotherapyconfrontingpresenthurdlesandunveilingupcomingopportunities AT kangdonghyun sarcomaimmunotherapyconfrontingpresenthurdlesandunveilingupcomingopportunities AT nohjeonghwan sarcomaimmunotherapyconfrontingpresenthurdlesandunveilingupcomingopportunities AT suhjooyeon sarcomaimmunotherapyconfrontingpresenthurdlesandunveilingupcomingopportunities AT kimjunehyuk sarcomaimmunotherapyconfrontingpresenthurdlesandunveilingupcomingopportunities AT youhyejin sarcomaimmunotherapyconfrontingpresenthurdlesandunveilingupcomingopportunities AT kanghyunguy sarcomaimmunotherapyconfrontingpresenthurdlesandunveilingupcomingopportunities AT kimyijun sarcomaimmunotherapyconfrontingpresenthurdlesandunveilingupcomingopportunities AT kimjinhong sarcomaimmunotherapyconfrontingpresenthurdlesandunveilingupcomingopportunities |